Radical Hysterectomy for Early Stage Cervical Cancer.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
15 09 2022
Historique:
received: 11 08 2022
revised: 09 09 2022
accepted: 13 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 28 9 2022
Statut: epublish

Résumé

Radical hysterectomy and plus pelvic node dissection are the primary methods of treatment for patients with early stage cervical cancer. During the last decade, growing evidence has supported the adoption of a minimally invasive approach. Retrospective data suggested that minimally invasive surgery improves perioperative outcomes, without neglecting long-term oncologic outcomes. In 2018, the guidelines from the European Society of Gynaecological Oncology stated that a "minimally invasive approach is favored" in comparison with open surgery. However, the phase III, randomized Laparoscopic Approach to Cervical Cancer (LACC) trial questioned the safety of the minimally invasive approach. The LACC trial highlighted that the execution of minimally invasive radical hysterectomy correlates with an increased risk of recurrence and death. After its publication, other retrospective studies investigated this issue, with differing results. Recent evidence suggested that robotic-assisted surgery is not associated with an increased risk of worse oncologic outcomes. The phase III randomized Robotic-assisted Approach to Cervical Cancer (RACC) and the Robotic Versus Open Hysterectomy Surgery in Cervix Cancer (ROCC) trials will clarify the pros and cons of performing a robotic-assisted radical hysterectomy (with tumor containment before colpotomy) in early stage cervical cancer.

Identifiants

pubmed: 36141917
pii: ijerph191811641
doi: 10.3390/ijerph191811641
pmc: PMC9517651
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

J Laparoendosc Adv Surg Tech A. 2015 Dec;25(12):990-8
pubmed: 26584414
N Engl J Med. 2018 Nov 15;379(20):1955-1957
pubmed: 30379600
J Gynecol Oncol. 2021 Nov;32(6):e83
pubmed: 34431254
Eur J Surg Oncol. 2015 Jan;41(1):34-9
pubmed: 25468458
N Engl J Med. 2018 Nov 15;379(20):1905-1914
pubmed: 30379613
J Gynecol Oncol. 2017 May;28(3):e34
pubmed: 28382797
Int J Gynecol Cancer. 2020 Sep;30(9):1269-1277
pubmed: 32788262
Eur J Surg Oncol. 2012 Mar;38(3):203-9
pubmed: 22244909
Int J Gynecol Cancer. 2022 Feb;32(2):117-124
pubmed: 35039455
Lancet Oncol. 2020 Jun;21(6):851-860
pubmed: 32502445
Int J Gynecol Cancer. 2018 May;28(4):641-655
pubmed: 29688967
N Engl J Med. 2021 Apr 29;384(17):1669-1671
pubmed: 33913646
Int J Gynaecol Obstet. 2020 Oct;151(1):43-48
pubmed: 32511745
J Natl Compr Canc Netw. 2020 Jun;18(6):660-666
pubmed: 32502976
Gynecol Oncol. 2019 Jul;154(1):89-94
pubmed: 31000470
J Clin Med. 2021 Oct 21;10(21):
pubmed: 34768345
Asian Pac J Cancer Prev. 2021 Jan 01;22(1):93-97
pubmed: 33507684
BJOG. 2019 Jul;126(8):956-959
pubmed: 30658010
J Minim Invasive Gynecol. 2021 Jan;28(1):117-123
pubmed: 32320800
J Minim Invasive Gynecol. 2022 Jul;29(7):840-847
pubmed: 35405331
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Front Oncol. 2021 Jun 10;11:683231
pubmed: 34178675
Gynecol Oncol. 2022 Sep;166(3):417-424
pubmed: 35879128
JAMA Oncol. 2020 Jul 1;6(7):1019-1027
pubmed: 32525511
J Gynecol Oncol. 2017 Nov;28(6):e82
pubmed: 29027400
Ann Surg Oncol. 2022 Feb;29(2):1151-1160
pubmed: 34545531
Eur J Obstet Gynecol Reprod Biol. 2022 Aug;275:64-69
pubmed: 35753229
Cancers (Basel). 2022 Apr 24;14(9):
pubmed: 35565246
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Int J Gynecol Cancer. 2015 Mar;25(3):493-7
pubmed: 25628110
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:28-44
pubmed: 34669203
BMC Cancer. 2015 Nov 24;15:928
pubmed: 26596955
Int J Gynecol Cancer. 2020 Jul;30(7):987-992
pubmed: 32448809
Am J Obstet Gynecol. 2020 Mar;222(3):249.e1-249.e10
pubmed: 31586602
BMC Cancer. 2022 Mar 26;22(1):331
pubmed: 35346103
Gynecol Oncol. 2022 Sep;166(3):561-566
pubmed: 35909005
Int J Gynecol Cancer. 2021 Dec;31(12):1617
pubmed: 34716176
Acta Obstet Gynecol Scand. 2019 Nov;98(11):1398-1403
pubmed: 31242322
Lancet Oncol. 2019 Sep;20(9):1198-1199
pubmed: 31383546
N Engl J Med. 2018 Nov 15;379(20):1895-1904
pubmed: 30380365

Auteurs

Giorgio Bogani (G)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Violante Di Donato (V)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Giovanni Scambia (G)

Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00182 Rome, Italy.

Francesco Raspagliesi (F)

Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milan, Italy.

Vito Chiantera (V)

Department of Gynecologic Oncology, University of Palermo, 90127 Palermo, Italy.

Giulio Sozzi (G)

Department of Gynecologic Oncology, University of Palermo, 90127 Palermo, Italy.

Tullio Golia D'Augè (T)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Ludovico Muzii (L)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Pierluigi Benedetti Panici (P)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Ottavia D'Oria (O)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Enrico Vizza (E)

Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS "Regina Elena" National Cancer Institute, 00144 Rome, Italy.

Andrea Giannini (A)

Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00185 Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH